Impax's PD candidate meets Phase III endpoint

Impax Laboratories Inc. (NASDAQ:IPXL) said thrice-daily oral IPX066 met the primary endpoint in the Phase III APEX-PD trial to treat Parkinson's disease. The extended-release combination of carbidopa and levodopa significantly improved the sum of Unified Parkinson's Disease Rating Scale Parts II and III scores from baseline to week 30 vs. placebo (p<0.0001). Impax has an SPA from FDA for the double-blind, international trial, which enrolled 381 patients with early PD. ...